

PERSONAL INFORMATION

Pierluigi di Mauro

✉ pierluigi.dimauro@istitutotumori.mi.it

Date of birth 07/10/1992

PROFESSIONAL EXPERIENCE

From 12/2024

Medical OncologistFondazione IRCCS Istituto Nazionale dei Tumori
Via Venezian, 1, 20133 Milano (Italia)

Department Medical Oncology 2

12/2023 – 11/2024

Medical OncologistASST Spedali Civili di Brescia
Piazzale Spedali Civili, 1, 25123 Brescia (Italia)

Department Medical Oncology

02/2022 – 10/2023

Resident PhysicianASST Spedali Civili di Brescia
Piazzale Spedali Civili, 1, 25123 Brescia (Italia)

Department Medical Oncology

07/2020 – 01/2022

Resident PhysicianOspedale San Gerardo, ASST Monza
Via Pergolesi 33, 20900 Monza (Italia)

Department Medical Oncology

11/2018 – 06/2020

Resident PhysicianASST Spedali Civili di Brescia
Piazzale Spedali Civili, 1, 25123 Brescia (Italia)

Department Medical Oncology

EDUCATION

11/2023

Postgraduate diploma in Medical Oncology

Università degli Studi di Brescia, Brescia (Italia)

Votazione 50/50 cum laude.

09/2011–03/2018

Medical Degree

Università degli Studi di Brescia, Brescia (Italy)

Votazione 110/110 cum laude and honors.

09/2006–07/2011

High School

Liceo Scientifico N. Copernico, Brescia (Italy)

Grade 100/100 cum laude.

PERSONAL COMPETENCES

First language Italian

Other languages

	Listening		Speaking		Writing
	Oral	Verbal	Interaction	Oral presentation	
inglese	B2	B2	B2	B2	B2
Diploma Cambridge English: First (FCE)					
tedesco	B2	B2	B2	B2	B2
Goethe-Zertifikat B2					

Quadro Comune Europeo di Riferimento delle Lingue

Professional expertise

First author or coauthor of poster presentations in national (AIOM) and international congresses (ESMO, ESMO Breast Cancer, SABCS, CTOS).

Speaker at National Conferences and training courses in Medical Oncology.

Participant in National and International Conferences in Medical Oncology.

First author and/or coauthor of 27 scientific articles in National and International peer-reviewed journals.

Digital expertise

Excellent knowledge of Microsoft Office Programs.

Good knowledge of major statistical software platforms (SPSS, Epi Info).

Driving license

B

FURTHER INFORMATION

Trattamento dei dati personali

Autorizzo il trattamento dei dati personali contenuti nel mio curriculum vitae in base all'art. 13 del D. Lgs. 196/2003 e all'art. 13 del Regolamento UE 2016/679 relativo alla protezione delle persone fisiche con riguardo al trattamento dei dati personali.

LIST OF PUBLICATIONS

1. Pedersini R, di Mauro P, Amoroso V, Parati MC, Turla A, Ghilardi M, Vassalli L, Ardine M, Volta AD, Monteverdi S, Borgonovo K, Ghidini A, Cabiddu M, Simoncini EL, Petrelli F, Berruti A, Barni S. Efficacy of Eribulin mesylate in older patients with breast cancer: A pooled analysis of clinical trial and real-world data. J Geriatr Oncol. 2020 Jul;11(6):976-981. doi: 10.1016/j.jgo.2020.03.021. Epub 2020 Apr 13. PMID: 32299685.
2. Pedersini R, Fornaro C, di Mauro P, Bianchi S, Vassalli L, Amoroso V, Gelmi M, Ardine M, Rodella F, Cosentini D, Dalla Volta A, Turla A, Pierini M, Motta P, Conti E, Simoncini EL, Berruti A. Efficacy of the DigniCap System in preventing chemotherapy-induced alopecia in breast cancer patients is not related to patient characteristics or side effects of the device. Int J Nurs Pract. 2021 Jun;27(3):e12888. doi: 10.1111/ijn.12888. Epub 2020 Sep 22. PMID: 32959460.
3. Pilla L, Alberti A, Di Mauro P, Gemelli M, Cogliati V, Cazzaniga ME, Bidoli

P, Maccalli C. Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects. *Cancers (Basel)*. 2020 Nov 20;12(11):3456. doi: 10.3390/cancers12113456. PMID: 33233603; PMCID: PMC7699774.

4. di Mauro P, Ferrari V. Bronchoesophageal Fistula. *N Engl J Med*. 2020 Dec 17;383(25):e137. doi: 10.1056/NEJMicm2018535. PMID: 33326718.

5. Monteverdi S, Pedersini R, Gallo F, Maffezzoni F, Dalla Volta A, Di Mauro P, Turla A, Vassalli L, Ardine M, Formenti AM, Simoncini EL, Giustina A, Maroldi R, Amoroso V, Berruti A. The Interaction of Lean Body Mass With Fat Body Mass Is Associated With Vertebral Fracture Prevalence in Women With Early Breast Cancer Undergoing Aromatase Inhibitor Therapy. *JBMR Plus*. 2020 Dec 21;5(2):e10440. doi: 10.1002/jbm4.10440. PMID: 33615109; PMCID: PMC7872339.

6. Pedersini R, di Mauro P, Bosio S, Zanini B, Zanini A, Amoroso V, Turla A, Vassalli L, Ardine M, Monteverdi S, Zamparini M, Gurizzan C, Cosentini D, Ricci C, Simoncini EL, Berruti A. Changes in eating habits and food preferences in breast cancer patients undergoing adjuvant chemotherapy. *Sci Rep*. 2021 Jun 21;11(1):12975. doi: 10.1038/s41598-021-92138-7. PMID: 34155246; PMCID: PMC8217237.

7. Bossi P, Gurizzan C, Lorini L, di Mauro P, Sardini C, Merlano M. Not all hematopoietic growth factors are created equal: should we gain information for their use with immunotherapy? *J Immunother Cancer*. 2021 Aug;9(8):e003154. doi: 10.1136/jitc-2021-003154. Erratum in: *J Immunother Cancer*. 2021 Nov;9(11): PMID: 34429333; PMCID: PMC8386202.

8. Gurizzan C, Pedersini R, Fornaro C, Sardini C, Zamparini M, Monteverdi S, Tovazzi V, Cosentini D, Dalla Volta A, Baggi A, Turla A, Di Mauro P, Lorini L, Laganà M, Bianchi S, Grisanti S, Consoli F, Conti E, Bossi P, Berruti A. Accurate Triage of Oncological Patients for Safely Continuing Cancer Therapy During the SARS-CoV-2 Pandemic. *Front Oncol*. 2021 Oct 14;11:707346. doi: 10.3389/fonc.2021.707346. PMID: 34722252; PMCID: PMC8552044.

9. Cazzaniga ME, Vallini I, Montagna E, Amoroso D, Berardi R, Butera A, Cagossi K, Cavanna L, Ciccarese M, Cinieri S, Cretella E, De Conciliis E, Febbraro A, Ferraù F, Ferzi A, Baldelli A, Fontana A, Gambaro AR, Garrone O, Gebbia V, Generali D, Gianni L, Giovanardi F, Grassadonia A, Leonardi V, Marchetti P, Sarti S, Musolino A, Nicolini M, Putzu C, Riccardi F, Santini D, Saracchini S, Sarobba MG, Schintu MG, Scognamiglio G, Spadaro P, Taverniti C, Toniolo D, Tralongo P, Turetti A, Valenza R, Valerio MR, Vici P, Di Mauro P, Cogliati V, Capici S, Clivio L, Torri V; VICTOR Study Group. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study. *Breast Cancer Res Treat*. 2021 Dec;190(3):415-424. doi: 10.1007/s10549-021-06375-5. Epub 2021 Sep 21. PMID: 34546500; PMCID: PMC8558172.

10. Cogliati V, Capici S, Pepe FF, di Mauro P, Riva F, Cicchiello F, Maggioni C, Cordani N, Cerrito MG, Cazzaniga ME. How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story. *Life* (Basel). 2022 Mar 5;12(3):378. doi: 10.3390/life12030378. PMID: 35330128; PMCID: PMC8954717.
11. di Mauro P, Capici S, Cogliati V, Pepe FF, Maggioni C, Riva F, Cicchiello F, Cazzaniga ME. Exceptional disease control with neratinib monotherapy in HER2-positive advanced breast cancer: A case report. *Current Problems in Cancer: Case Reports*. 2022, 6:100167. doi: 10.1016/j.cpcr.2022.100167.
12. Pedersini R, Zamparini M, Bosio S, di Mauro P, Turla A, Monteverdi S, Zanini A, Amoroso V, Vassalli L, Cosentini D, Grisanti S, Simoncini EL, Berruti A. Taste alterations during neo/adjuvant chemotherapy and subsequent follow-up in breast cancer patients: a prospective single-center clinical study. *Support Care Cancer*. 2022 Aug;30(8):6955-6961. doi: 10.1007/s00520-022-07091-6. Epub 2022 May 11. PMID: 35538327.
13. Pedersini R, Di Mauro P, Zamparini M, Bosio S, Zanini B, Amoroso V, Turla A, Monteverdi S, Zanini A, Laini L, Schivardi G, Vassalli L, Cosentini D, Grisanti S, Simoncini EL, Berruti A. Taste Alterations Do Not Affect Change in Food Habits and Body Weight in Breast Cancer Patients. *In Vivo*. 2022 Jul-Aug;36(4):1860-1867. doi: 10.21873/invivo.12904. PMID: 35738619; PMCID: PMC9301449.
14. Pedersini R, di Mauro P, Amoroso V, Castronovo V, Zamparini M, Monteverdi S, Laini L, Schivardi G, Cosentini D, Grisanti S, Marelli S, Ferini Strambi L, Berruti A. Sleep disturbances and restless legs syndrome in postmenopausal women with early breast cancer given adjuvant aromatase inhibitor therapy. *Breast*. 2022 Dec;66:162-168. doi: 10.1016/j.breast.2022.10.006. Epub 2022 Oct 18. PMID: 36288635; PMCID: PMC9593725.
15. Esposito A, Stucchi E, Baronchelli M, Di Mauro P, Ferrari M, Lorini L, Gurizzan C, London NRJ, Hermsen M, Lechner M, Bossi P. Molecular Basis and Rationale for the Use of Targeted Agents and Immunotherapy in Sinonasal Cancers. *J Clin Med*. 2022 Nov 16;11(22):6787. doi: 10.3390/jcm11226787. PMID: 36431263; PMCID: PMC9698911.
16. Gemelli M, Cortinovis DL, Baggi A, di Mauro P, Calza S, Berruti A, Grisanti S, Rota M. Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis. *Cancers* (Basel). 2022 Dec 9;14(24):6063. doi: 10.3390/cancers14246063. PMID: 36551550; PMCID: PMC9775536.
17. Pedersini R, Cosentini D, Rinaudo L, Zamparini M, Ulivieri FM, di Mauro P, Maffezzoni F, Monteverdi S, Vena W, Laini L, Amoroso V, Simoncini EL, Farina D, Mazziotti G, Berruti A. Assessment of DXA derived bone quality indexes and bone geometry parameters in early breast cancer patients: A single center cross-sectional study. *Bone Rep*. 2023 Jan 11;18:101654. doi:

10.1016/j.bonr.2023.101654. PMID: 36700242; PMCID: PMC9868326.

18. di Mauro P, Schivardi G, Pedersini R, Laini L, Esposito A, Amoroso V, Laganà M, Grisanti S, Cosentini D, Berruti A. Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report. *Front Oncol.* 2023 Feb 20;13:1139372. doi: 10.3389/fonc.2023.1139372. PMID: 36890829; PMCID: PMC9987211.

19. Zattarin E, Presti D, Mariani L, Sposetti C, Leporati R, Menichetti A, Corti C, Benvenuti C, Fucà G, Lobefaro R, Ligorio F, Provenzano L, Vingiani A, Del Vecchio M, Griguolo G, Sirico M, Bernocchi O, Marra A, Zagami P, Agostinetto E, Jacobs F, Di Mauro P, Esposito A, Giorgi CA, Lalli L, Boldrini L, Giacchetti PPB, Schianca AC, Guarneri V, Pedersini R, Losurdo A, Zambelli A, Generali D, Criscitiello C, Curigliano G, Pruneri G, de Braud F, Dieci MV, Vernieri C. Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors. *NPJ Breast Cancer.* 2023 Apr 17;9(1):27. doi: 10.1038/s41523-023-00534-1. PMID: 37069173.

20. Dalla Volta A, Caramella I, Di Mauro P, Bergamini M, Cosentini D, Valcamonico F, Cappelli C, Laganà M, Di Meo N, Farina D, Pedersini R, Mazziotti G, Berruti A. Role of Body Composition in the Prediction of Skeletal Fragility Induced by Hormone Deprivation Therapies in Cancer Patients. *Curr Oncol Rep.* 2023 Oct;25(10):1141-1152. doi: 10.1007/s11912-023-01447-9. Epub 2023 Aug 25. PMID: 37624550; PMCID: PMC10556180.

21. Pedersini R, Laganà M, Bosio S, Zanini B, Cosentini D, di Mauro P, Alberti A, Schivardi G, Laini L, Ippolito G, Amoroso V, Vassalli L, Simoncini EL, Berruti A, Donato F. Is weight gain preventable in women with early breast cancer undergoing chemotherapy? A real-world study on dietary pattern, physical activity, and body weight before and after chemotherapy. *Breast Cancer Res Treat.* 2023 Dec;202(3):461-471. doi: 10.1007/s10549-023-07095-8. Epub 2023 Sep 11. PMID: 37695400; PMCID: PMC10564810.

22. Zattarin E, Mariani L, Menichetti A, Leporati R, Provenzano L, Ligorio F, Fucà G, Lobefaro R, Lalli L, Vingiani A, Nichetti F, Griguolo G, Sirico M, Bernocchi O, Marra A, Corti C, Zagami P, Agostinetto E, Jacobs F, Di Mauro P, Presti D, Sposetti C, Giorgi CA, Guarneri V, Pedersini R, Losurdo A, Generali D, Curigliano G, Pruneri G, de Braud F, Dieci MV, Vernieri C. Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors. *Ther Adv Med Oncol.* 2023 Dec 20;15:17588359231204857. doi: 10.1177/17588359231204857. PMID: 38130467; PMCID: PMC10734364.

23. Cosentini D, Pedersini R, Di Mauro P, Zamparini M, Schivardi G, Rinaudo L, Di Meo N, Del Barba A, Cappelli C, Laganà M, Alberti A, Baronchelli M, Guerci G, Laini L, Grisanti S, Simoncini EL, Farina D, Mazziotti G, Berruti A; Bone Health Group of the ASST Spedali Civili, Brescia. Fat Body Mass and Vertebral Fracture Progression in Women With Breast Cancer. *JAMA Netw Open.* 2024 Jan

2;7(1):e2350950. doi: 10.1001/jamanetworkopen.2023.50950. PMID: 38198137; PMCID: PMC10782249

24. Pedersini R, Buffoni M, Petrelli F, Ghidini A, di Mauro P, Amoroso V, Parati MC, Laini L, Cosentini D, Schivardi G, Ippolito G, Berruti A, Laganà M. Gastrointestinal Toxicity of Antibody Drug Conjugates (ADCs) in Metastatic Breast Cancer: A Pooled Analysis. *Clin Breast Cancer*. 2024 Jul;24(5):411-420. doi: 10.1016/j.clbc.2024.04.003. Epub 2024 Apr 8. PMID: 38734491.

25. Pedersini R, Schivardi G, Laini L, Zamparini M, Bonalumi A, di Mauro P, Bosio S, Amoroso V, Villa N, Alberti A, Di Meo N, Gonano C, Zanini B, Laganà M, Ippolito G, Rinaudo L, Farina D, Castellano M, Cappelli C, Simoncini EL, Cosentini D, Berruti A. Changes in body composition in early breast cancer patients treated with aromatase inhibitors. *J Endocrinol Invest*. 2024 Jun 10. doi: 10.1007/s40618-024-02401-7. Epub ahead of print. PMID: 38856966.

26. Fassi E, Amoroso V, Cosentini D, Ferrari V, Laganà M, Berruti A, di Mauro P. Regorafenib-related erythrocytosis in metastatic extra-gastrointestinal stromal tumor: a case report. *Front Oncol*. 2024 Aug 6;14:1398055. doi: 10.3389/fonc.2024.1398055. PMID: 39165680; PMCID: PMC11333830.

27. Pedersini R, Schivardi G, Laganà M, Laini L, di Mauro P, Zamparini M, Amoroso V, Bonalumi A, Bosio S, Zanini B, Buizza C, Villa N, Ravanelli M, Rinaudo L, Grisanti S, Farina D, Berruti A, Donato F, Cosentini D. Body composition in early breast cancer patients treated with adjuvant aromatase inhibitors: Does dietary counseling matter? *Breast*. 2024 Aug 31;78:103794. doi: 10.1016/j.breast.2024.103794. Epub ahead of print. PMID: 39265313.

Milano, 30/12/2024